Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel corona virus disease (COVID-19). To date, no prophylactic vaccines or approved therapeutic agents are available for preventing and treating this highly transmittable disease. Here we report two monoclonal antibodies (mAbs) cloned from memory B cells ... of patients recently recovered from COVID-19, and both mAbs specifically bind to the spike (S) protein of SARS-CoV-2, block the binding of receptor binding domain (RBD) of SARS-CoV-2 to human angiotensin converting enzyme 2 (hACE2), and effectively neutralize S protein-pseudotyped virus infection. These human mAbs hold the promise for the prevention and treatment of the ongoing pandemic of COVID-19.
Mesh Terms:
Adult, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Cloning, Molecular, HEK293 Cells, Humans, Protein Binding, Receptor, Angiotensin, Type 2, Spike Glycoprotein, Coronavirus
Adult, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Cloning, Molecular, HEK293 Cells, Humans, Protein Binding, Receptor, Angiotensin, Type 2, Spike Glycoprotein, Coronavirus
Cell Mol Immunol
Date: Dec. 01, 2019
PubMed ID: 32313207
View in: Pubmed Google Scholar
Download Curated Data For This Publication
221565
Switch View:
- Interactions 1